STOCK TITAN

Alkermes plc. (ALKS) SEC Filings, Feb 2-20, 2026

ALKS NASDAQ

Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.

Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.

Rhea-AI Summary

Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported equity compensation-related share movements, primarily from restricted stock units (RSUs) converting into ordinary shares. On February 18 and 19, 2026, RSU awards for 8,897 and 7,673 units were exercised, each unit representing one ordinary share.

To cover tax obligations associated with these vestings, 3,504 and 3,407 ordinary shares were automatically withheld and disposed of at prices of $32.02 and $32.00 per share, respectively, characterized as payment of tax liability rather than open-market sales. Following these transactions, Hopkinson directly owned 81,031 Alkermes ordinary shares. One referenced RSU award is noted as fully vested, while another vests in four equal annual installments starting on February 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

Alkermes plc executive David Joseph Gaffin reported multiple equity award transactions. On February 18 and 19, 2026, he exercised restricted stock unit awards into ordinary shares, with each unit converting into one ordinary share.

He acquired 7,673 ordinary shares and 6,355 ordinary shares through derivative exercises at a stated price of $0.00 per share. On the same dates, he disposed of 3,407 and 2,126 ordinary shares, respectively, to cover tax liabilities through share withholding. After these transactions, his directly held ordinary shares totaled 231,602. One award is fully vested, while another vests in four equal annual installments starting on February 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

Baker Bros. Advisors LP and related entities filed a Schedule 13G reporting beneficial ownership of 10,012,267 Alkermes plc ordinary shares, equal to 6.1% of the class, based on 165,117,509 shares outstanding as of October 24, 2025.

The shares are held through two investment funds: 667, L.P. with 845,828 shares (0.5%) and Baker Brothers Life Sciences, L.P. with 9,166,439 shares (5.6%). The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alkermes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
ownership
Rhea-AI Summary

Alkermes plc completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA‑approved narcolepsy drug LUMRYZ and a commercial team experienced in sleep medicine. The deal was executed via an Irish court‑sanctioned scheme of arrangement.

Avadel shareholders became entitled to receive $21.00 in cash per share plus one contingent value right that may pay an additional $1.50 per share if a specified milestone in the CVR agreement is met. Avadel will be delisted from Nasdaq and deregistered under U.S. securities laws.

To finance the Acquisition, Alkermes borrowed $1.525 billion under new senior secured term loan A and B facilities maturing in 2031 and used approximately $750 million of its cash. A prior bridge term loan facility of about $1.5 billion was terminated. Alkermes states the transaction is expected to be accretive in 2026 and to enhance its revenue growth profile while expanding its neuroscience portfolio and late‑stage pipeline in sleep and other neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
current report
-
Rhea-AI Summary

Alkermes plc Director and CEO Richard F. Pops reported two transactions in ordinary shares. On February 5, 2026, he acquired 149,580 ordinary shares at no cost from the vesting of performance-based restricted stock units granted in February 2023 after a three-year performance period.

On the same date, he disposed of 62,230 ordinary shares at $33.55 per share. Following these transactions, Pops beneficially owned 1,377,740 ordinary shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
insider
-
Rhea-AI Summary

Alkermes plc senior executive Christian Todd Nichols reported equity transactions in company ordinary shares. On February 5, 2026, he acquired 21,127 ordinary shares at no cost upon vesting of performance-based restricted stock units granted in 2023 after a three-year performance period.

On the same date, he reported a disposition of 6,389 ordinary shares at $33.55 per share. Following these transactions, Nichols directly owned 100,946 ordinary shares of Alkermes plc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
insider
Rhea-AI Summary

Alkermes plc executive Blair Curtis Jackson reported new share awards and a related share disposition. On February 5, 2026, Jackson acquired 28,810 ordinary shares at no cost from the vesting of performance-based restricted stock units granted on February 23, 2023, covering a three-year period that ended December 31, 2025. The vesting followed the determination that certain performance goals were achieved and a relative total shareholder return adjustment was applied.

On the same date, Jackson disposed of 8,626 ordinary shares at $33.55 per share in a transaction coded "F," and held 221,552 ordinary shares directly after these transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
insider
-
Form 4
Rhea-AI Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported equity compensation activity in the company’s ordinary shares. On February 5, 2026, he acquired 25,352 ordinary shares at no cost upon vesting of performance-vesting restricted stock units granted on February 23, 2023.

The vesting followed achievement of pre-set performance goals and application of a relative total shareholder return modifier, and represents the final vesting event under the 2023 PRSU awards. On the same date, 7,454 shares were disposed of at $33.55 per share (code F), typically indicating shares withheld or sold to cover tax obligations, leaving 75,638 shares held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
insider
-
Rhea-AI Summary

Alkermes plc executive David Joseph Gaffin reported equity compensation activity. On February 5, 2026, he acquired 25,352 ordinary shares at no cost when performance-vesting RSUs granted on February 23, 2023 vested after a three-year performance period ending December 31, 2025.

The same day, he disposed of 7,619 ordinary shares at $33.55 per share in a transaction coded “F.” After these transactions, he directly beneficially owned 223,107 ordinary shares of Alkermes plc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.20%
Tags
insider
Rhea-AI Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported option exercises and share sales in Alkermes ordinary shares. On February 2, 2026, he exercised an employee stock option for 5,000 shares at an exercise price of $19.34, converting it into ordinary shares. The filing shows two same-day sales of ordinary shares: 5,000 shares sold at a weighted average price of $34.2449 and 4,000 shares sold at $33.54. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the reported trades, Hopkinson directly owns 57,740 ordinary shares and holds 26,356 employee stock options that are fully vested in accordance with their terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
insider

FAQ

How many Alkermes plc. (ALKS) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Alkermes plc. (ALKS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alkermes plc. (ALKS)?

The most recent SEC filing for Alkermes plc. (ALKS) was filed on November 12, 2026.